Madhuri Kodikonda, Naik Prakash Ramachandra
a Department of studies in Zoology, Endocrinology Research Laboratory , University of Mysore , Mysuru , Karnataka (S) , India.
b Department of studies in Zoology , University of Mysore , Mysuru , Karnataka (S) , India.
Arch Physiol Biochem. 2017 Dec;123(5):322-329. doi: 10.1080/13813455.2017.1336632. Epub 2017 Jun 9.
The objective of the study was to evaluate the efficacy of garcinol as an antidiabetic candidate in streptozotocin-induced diabetic Wistar rats. Diabetic rats showed a significant increase in the biochemical parameters such as fasting blood glucose, glycated haemoglobin, urea, alanine aminotransferase and aspartate aminotransferase, malondialdehyde, total cholesterol, triglycerides, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, atherogenic index and a significant decrease in plasma insulin, HOMA-β-cell functioning index, glycogen, high-density lipoprotein cholesterol, body weight and antioxidant enzyme activities, viz. superoxide dismutase, catalase and reduced glutathione. Oral administration of garcinol (10 and 20 mg/kg body weight/day) for 30 days improved the above-mentioned alterations. The effect produced by the drug was compared with that of glibenclamide, a standard hypoglycaemic drug. These findings reveal that garcinol can be a promising antidiabetic candidate in the future.
本研究的目的是评估藤黄酸作为抗糖尿病候选药物对链脲佐菌素诱导的糖尿病Wistar大鼠的疗效。糖尿病大鼠的生化参数显著升高，如空腹血糖、糖化血红蛋白、尿素、丙氨酸转氨酶和天冬氨酸转氨酶、丙二醛、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、极低密度脂蛋白胆固醇、动脉粥样硬化指数，而血浆胰岛素、HOMA-β细胞功能指数、糖原、高密度脂蛋白胆固醇、体重和抗氧化酶活性则显著降低，即超氧化物歧化酶、过氧化氢酶和还原型谷胱甘肽。口服藤黄酸（10和20毫克/千克体重/天）30天可改善上述变化。将该药物产生的效果与标准降糖药物格列本脲的效果进行了比较。这些发现表明，藤黄酸未来可能是一种有前景的抗糖尿病候选药物。
